Comparison of roxatidine and famotidine on nocturnal gastric juice secretion.
Adult patients with symptoms of gastric disease were randomly assigned to two treatment groups (roxatidine group, n = 115; famotidine group, n = 113) or untreated control group (placebo, n = 111). The treatment groups randomly received 75 mg of roxatidine or 20 mg of famotidine at 9 pm, and 12 - 13 h later gastric juice secretion was measured with gastric X-ray films in both groups. Mean gastric juice secretion was significantly lower in the treated groups (roxatidine, 16.1 ml/12 h; famotidine, 19.9 ml/12 h) than in the untreated controls (placebo, 49.5 ml/12 h). Gastric juice suppression by roxatidine and by famotidine, respectively, was 82% and 37% in patients with gastric ulcer; 71% and 39% in patients with duodenal ulcer; 70% and 64% in patients with gastritis; and 68% and 86% in patients with no evidence of disease. It is concluded that roxatidine was more effective than famotidine for gastric juice suppression in patients with peptic ulcer. In patients with no evidence of gastric disease, however, famotidine was more effective than roxatidine.
Tanioka
H
H
Department of Radiology, Tanioka Clinic, Kashiwa, Japan.
Kaga
K
K
D000328:Adult; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D004381:Duodenal Ulcer / Q000188:drug therapy / Q000503:physiopathology; D015738:Famotidine / Q000627:therapeutic use*; D005260:Female; D005750:Gastric Juice / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000378:metabolism*; D005756:Gastritis / Q000188:drug therapy / Q000503:physiopathology; D005767:Gastrointestinal Diseases / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010880:Piperidines / Q000627:therapeutic use*; D011859:Radiography; D013276:Stomach Ulcer / Q000188:drug therapy / Q000503:physiopathology
D000897:Anti-Ulcer Agents; D010880:Piperidines; D015738:Famotidine; C053742:roxatidine acetate